Novavax NVAX shares are trading lower amid reports competing COVID-19 vaccines may be approved in Europe. The stock also dipped on reports the company is unlikely to seek emergency use authorization for its COVID-19 vaccine until June.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.
At the time of publication, shares of Novavax were trading 8.14% lower at $161.67. The stock has a 52-week low of $19.62 and a 52-week high of $331.68
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
